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SUMMARY
Objective. Medication-related osteonecrosis of the jaw (MRONJ) is a rare complication of 
antiresorptive or antiangiogenetic therapy that manifests as an exposed bone with clinical signs 
of infection, persisting for more than 8 weeks, without history of radiation therapy or metastases 
to the jaws. The aim of the study was to describe the incidence, risk factors, staging process and 
clinical course of MRONJ in patients with multiple myeloma (MM).
Materials and methods. We retrospectively analyzed all (126) newly diagnosed MM patients 
at Riga East Clinical University Hospital (Riga. Latvia) from June 2014 to June 2017.
Results. Among 88 MM patients treated with bisphosphonates (BP), 6 (6.8%) patients de-
veloped MRONJ. All six patients received intravenous nitrogen-containing BPs. The average 
time until MRONJ manifestation was under two years. For our patients the severity of MRONJ 
was stage I in two, stage II in three, and stage III in one patient. Five patients had MRONJ of 
mandibula and one of maxilla. All patients with MRONJ had undergone a dental extraction or a 
trauma before the development of MRONJ.
Conclusion. We found that MRONJ correlated with the patient’s age. The average time until 
MRONJ manifestation in reserach group is 2 years. One of triggerring MRONJ factors are tooth 
extraction or trauma. 
Key words: medication-related osteonecrosis of the jaw, bisphosphonates, multiple my-
eloma, osteonecrosis.
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INTRODUCTION
Multiple myeloma (MM) is a malignant plasma 
cell disorder that accounts for approximately 10 per-
cent of all hematologic malignancies (1). According to 
the Centers for Disease Control and Prevention (CDC), 
the annual incidence in the United States of America 
(USA) is approximately 4 to 5 per 100.000 (2, 3). In 
general, worldwide, there are approximately 154.000 
cases and 101.000 deaths per year attributed to MM 
(4). Lytic skeletal lesions are present at the time of 
diagnosis in approximately 60 percent of patients with 
MM and almost all patients with MM will have lytic 
bone lesions at some point in their diseases course (5).
In Latvia treatment of MM includes chemo-
therapy with cyclophosphamide, bortezomibe, 
corticosteroids (dexamethasone), erythropoietin, 
calcium, vitamin-D, autologous stem cell trans-
plantation (ASCT) and bisphosphonates (BPs). BPs 
are widely used in the management of lytic bone 
lesions as addition to other therapies directed at 
the malignant plasma cell clone (6, 7). They do not 
repair existing bone damage but they prevent the 
development of new lesions. BPs do not improve 
overall survival or progression-free survival but 
have a benefi cial impact on pain control, and act as 
an adjunct to radiation therapy or surgical interven-
tion to stabilize fractures or impending fractures (6, 
8-14). The BPs mechanism of action is the inhibition 
of bone resorption by suppressing osteoclast activa-
tion and inducing osteoclast apoptosis. They also 
have anti-angiogenic properties, activate T-cells and 
have direct anti-tumor activity (15, 16). The overall 
effect is decreased bone turnover and inhibition 
of the bone’s reparative ability (17-19). However. 
BPs usage has side effects. Medication-related os-
teonecrosis of the jaw (MRONJ) is the main side 
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effect of treatment with BPs (20). It is attributed 
to the fact that alveolar bone of jaws has very high 
turnover rates therefore BPs accumulate in alveolar 
bone. Corticosteroids and chemotherapy increase 
the vulnerability of the oral mucosa and reduce its 
nutritive supply, posses an anti-angiogenic effect 
by inhibiting vascular endothelial growth factor and 
fi broblast growth factor (20).
MRONJ strongly correlates with age because 
of physiological effects of aging, including infl am-
matory issues, immune dysfunction, a reduction in 
blood fl ow and bone remodelling ability (10).
According to the American Association of Oral 
and Maxillofacial Surgeons (AAOMS) MRONJ is 
confi rmed if these three points are fulfi lled: 1 – cur-
rent or previous treatment with bisphosphonates, 
denosumab or antiangiogenic agents; 2 – exposed 
bone or bone that can be probed through an intraoral 
or extraoral fi stula in the maxillofacial region that 
has persisted for more than 8 weeks; 3 – no history 
of radiation therapy or obvious metastatic disease 
to the jaws (30). MRONJ is diagnosed by using 
panoramic radiography, computed tomography (CT) 
and clinical signs and symptoms. Despite multiple 
diagnostic methods available, the radiographic fea-
tures of MRONJ are relatively nonspecifi c (5, 30).
The management of MRONJ remains contro-
versial and there is no defi nitive standard of care 
for this disese. Non-surgical, conservative, and 
minimally invasive treatment regiments for MRONJ 
are considered useful to control the disease, leading 
to predictable good results in cases of lower stages 
of MRONJ (10).
MATERIAL AND METHODS
We retrospectively analyzed all 126 newly diag-
nosed MM patients at Riga East Clinical University 
Hospital (Riga, Latvia) from June 2014 to June 
2017. Bone lesions were detected by either radiog-
raphy. CT, magnetic resonance imaging (MRI), or 
positron emission tomography (PET/CT). The stage 
of MRONJ was set according to the staging system 
proposed by AAOMS (5).
In accordance with International Myeloma 
Working Group recommendations, all MM patients 
with bone lesions received bisphosphonates (exclud-
ing patients with glomerular fi ltration rate (GFR) 
<30 ml/min). The BPs were administered either 
orally or intravenously (5).
The study design, patient’s information and con-
sent forms were approved by the Ethics Committee 
of Riga Stradins University and in accordance with 
the Declaration of Helsinki.
Descriptive statistics were used to analyse 
demographics and clinical characteristics of study 
population. Continuous variables were described as 
means (standard deviation (SD)). Data were analysed 
with t tests for independent samples. A two-sided p-
value <0.05 was considered statistically signifi cant. 
To understand whether differences were statistically 
meaningful Cochen's d value (<0.5 – small effect 
size, 0.5-0.8 – medium effect size, >0.8 – large effect 
size) for t-test was used. Statistical analyses were 
performed using IBM SPSS statistics (version 23 for 
Windows. IBM Corp.. Somers. NY. USA).
RESULTS
From all 126 MM patients enrolled in this study, 
70 (57%) were female and 53 (43%) were male. 
Patients in our study were aged 35-88 years, aver-
age age was 69.68 yrs. Lytic skeletal lesions were 
present at the time of diagnosis in 88 (69.84%), 
patients.
All patients with bone disease received treat-
ment with corticosteroids and 71 of them received 
chemotherapy. Of 88 patients with bone disease 84 
(95.45%) received intravenous BPs (zoledronic acid 
4 mg every 4 weeks) and 2 patients were treated 
with oral bisphosphonates and 2 more were treated 
with denosumab.
Among patients with MM treated with BPs, 
6 patients (6.8%) developed MRONJ. Their mean 
age was 72.8 yrs; SD=9.17 (62-88). Between these 
6 patients male to female ratio was 1:5. All six pa-
tients received intravenous nitrogen-containing BPs 
(Zoledronic acid). Average time until manifestation 
of MRONJ was 23.8 months; SD=5.41 months, 
range 17-33. For patients with MRONJ the severity 
of it was stage I in two patients, stage II in three, and 
stage III in one patient. Five patients had MRONJ 
of mandibula and one – of the maxilla. All patients 
with MRONJ had undergone a dental extraction or 
trauma before the development of this complication. 
The fi rst patient with MM who developed MRONJ 
in Latvia was among the patients who were included 
in this research. The patient was a female, 76 years 
old, with complaints about facial swelling, bone ex-
posure, and severe pain in the right premolar region 
of the mandible. These symptoms had developed 
2 months following a tooth extraction. Physical 
examination showed facial swelling, neck lymphad-
enopathy and cutaneous submandibular fi stula with 
pus discharge. Patient had history of MM, chronic 
kidney disease, anemia, vertebral fracture at Th12-
L1 level and myocardial infarction. In our study 
from 6 patients with MRONJ 5 had comorbidities: 
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3 – diabetes, 2 – hypertension. Especially diabetes 
is generally associated with with microvascular 
ischemia of the bone, endothelial cell dysfunction, 
decreased bone turnover and remodeling, resulting 
in a delayed wound healing and proneness to infec-
tion. According to Zhang Q et al., it is a established 
risc factor for MRONJ. 
The fi rst patient with MRONJ in Latvia had 
been diagnosed with MM and received intravenous 
zoledronic acid for 18 months (total dose was 72 
mg). CT scan (Figure) showed diffuse osteolysis 
with bone sclerosis, bone sequestration and destruc-
tion of the bone. Histological examination showed 
bacterial debris and granulation tissue with infi l-
tration of lymphocytes and histiocytes. Evidence 
of metastatic bone disease was not detected. The 
patient received conservative surgical treatment – 
debridement of the bone seqestrum, pain relief, 
antibiotic therapy for 10 days, hyperbaric oxygen 
therapy. Treatment with BPs was discontinued. This 
therapy stabilised the patient’s state. The wound 
healed without any further complications.
In our study, patients with MRONJ were on 
average older (mean age 72.83 years ) than other 
MM patients (mean age – 69.68 years). Independent 
sample t-test showed that patients in osteonecrosis 
group (M=72.83; SD=9.17 years) were older than 
other MM patients (M=69.68; SD=10.35 years), 
although without statistical signifi cance (p=0.46), 
however, calculating the size of the statistical effect 
using Cohen's d value, the effect is average (d=0.32). 
Research group patients data were summerized in 
Table. 
DISCUSSION
We found several factors that could be attribut-
able to the development of MRONJ. Since calcula-
tion of the statistical effect of patients’ on MRONJ 
development using Cohen’s d value found average 














1. 76 F R Md 18 months 3 Z i/v. S. Ch Yes
2. 72 F R Md 20 months 2 Z i/v. S. Ch No
3. 62 F R Md 25 months 2 Z i/v. S. Ch Yes
4. 65 M L Md 26 months 2 Z i/v. S. Ch No
5. 88 F L Mx 25 months 1 Z i/v. S. Ch No
6. 74 F R Md 34 months 1 Z i/v. S. Ch Yes
F – female. M – male. R – right. L – left. Md – mandible. Mx – maxilla. Z – acidi zoledronici. S – steroids. Ch – chemotherapy. 
*At the time of the complication.
Fig. Bisphonate-related osteonecrosis of the jaw in 76-year 
old female MM patient under BF therapy, after beeing 
subjected to a tooth extraction. A – clinical examination 
shows areas of bone exposure in the right side of mandible. 
B – fi stula in the submandibular skin. C – CT shows dif-
fuse osteolysis with bone sclerosis, bone sequestration and 
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